Center City 1528 Walnut Street Suite 1205 Philadelphia, PA 19102





King Of Prussia 216 Mall Blvd Suite#1 King Of Prussia, PA, 19046

OCREVUS ZUNOVOTM

(ocrelizumab and hyaluronidase-ocs	Date:			
	PATIEN	T INFORMATI	ON	
Name: Phone:			DOB:	SEX: M □ F □
□NKDA Allergies:		Weight lbs/kg:		
	PHYSICIA	N INFORMA	TION	
Physician Name:		Practice Name:		
Address:		Office Contact 1	Name:	Office Contact #:
Phone: Fax:		Email (for updat	es):	
	REFERE	RAL STATUS		
□New Referral □Referral Renewal □	□Medication/Order (Change □Benefi	ts Verification Only	□ Discontinuation Order
OCREVUS ZUNOVO is a CD20-dir Relapsing forms of multiple sclerosis (MS), to incorprogressive disease, in adults (1) Primary progressive MS, in adults (1)		•		tive secondary
□ ICD-10*:		WARNINGS AND PRECAUTIONS hhttps://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf		
PRE-MEDICATION Tylenol PO 650mg		PATIENT WEIGHTlbskg DOSAGE: Injection 920m; per 23ml (40 m vial) FREQQUENCY Every 6 months Other: LAB DRAW REC Labs: Freq:	g ocrelizumab and 23, g and 1,000 units/mL) for mont	000 units of hyaluronidase solution in a single-dose h
NOTES/ADDITIONAL COMMENTS:		REQUIRED DO	CUMENTATION CI	HECKLIST:
		Patient Demographics Insurance Card/Information Recent labs to include Hepatitis Panel and CBC, as well as CMP and quantitative, if available *Please send any other recent labs Recent Progress note and MRI of Brain Other		
ORDERING PROVIDER			Diagnosis Codo	
Signature X		Date		
Provider	Phone	Fax		